Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Is confidence a second thought—or part of the first one?
In some settings, neural circuits may calculate confidence in a decision simultaneously with the choice itself. That changes the types of questions researchers should ask.
Is confidence a second thought—or part of the first one?
In some settings, neural circuits may calculate confidence in a decision simultaneously with the choice itself. That changes the types of questions researchers should ask.
What AI can learn from hunger
To enhance AI safety, take a lesson from biological brains; a small set of wants maintains durable control over a much larger cognitive system.
What AI can learn from hunger
To enhance AI safety, take a lesson from biological brains; a small set of wants maintains durable control over a much larger cognitive system.
New projectome captures ‘complex beast’ of serotonin system in mice
The whole-brain map—the first of its kind in a vertebrate—identifies five distinct neuron groups.
New projectome captures ‘complex beast’ of serotonin system in mice
The whole-brain map—the first of its kind in a vertebrate—identifies five distinct neuron groups.